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Abstract
Background and objectives: Dexmedetomidine is a selective α2-agonist. There are 250-300 α2-
adrenoceptor on the surface of each human platelet and ephedrine induces platelet aggregation 
by binding these receptors. This study was designed to study platelet function after incubation 
with therapeutic concentrations of dexmedetomidine. 
Methods: The study was carried out on 18 healthy, non-smoking males, ages ranging 25 to 35 
years old. Because of the recommended therapeutic concentration range of dexmedetomidine 
obtained by intravenous infusion is 0.4-1.2 ng.mL-1, dexmedetomidine solutions were prepared 
in three different concentrations. The calculated value of dexmedetomidine solution and diluent 
without dexmedetomidine as control were added to the blood sample. Thus, we obtained 0, 
0.4, 0.8 and 1.2 ng.mL-1 dexmedetomidine concentrations of plasma. Each concentration of 
dexmedetomidine was incubated with whole blood at 37°C during 15 minutes. Then blood samples 
were centrifugated to prepare platelet-rich plasma and platelet-poor plasma. The platelet-rich 
plasma was diluted with the platelet-poor plasma to yield test platelet-rich plasma with a ﬁ nal 
platelet count of 250 ± 50 X 109.L-1. 
Results: The platelet aggregation amplitudes and slopes were statistically similar among all groups 
by the aggregation test, which were performed with ADP, collagen or epinephrine. 
Conclusion: Therapeutic concentrations of dexmedetomidine had no effect on the platelet 
functions in healthy individuals in vitro. 
© 2013 Sociedade Brasileira de Anestesiologia. Published by Elsevier Editora Ltda.   
In Vitro Effect of Dexmedetomidine on Platelet Aggregation
Emine Arzu Kosea,*, Oral Nevruzb, Mehtap Honcac, Vedat Yildirimd 
a Department of Anesthesiology and Reanimation, School of Medicine, Kirikkale University, Kirikkale, Turkey
b Department of Hematology, Gulhane Military Medical Academy, Ankara, Turkey
c Department of Anesthesiology and Reanimation, Kecioren Teaching and Medical Research Hospital, Ankara, Turkey
d Department of Anesthesiology and Reanimation, Gulhane Military Medical Academy, Ankara, Turkey
Received on August 27, 2012; accepted on September 11, 2012
KEYWORDS 
Dexmedetomidine; 
In Vitro;
Platelet aggregation
SCIENTIFIC ARTICLE
* Corresponding author. Department of Anesthesiology and Reanimation, School of Medicine, Kirikkale University, 71100-Kirikkale, Turkey.
E-mail: arzuhct@hotmail.com (E.A. Kose)
0104-0014      © 2013 Sociedade Brasileira de Anestesiologia. Published by Elsevier Editora Ltda. 
http://dx.doi.org/10.1016/j.bjane.2012.09.007
Este é um artigo Open Access sob a licença de CC BY-NC-ND
Este é um artigo Open Access sob a licença de CC BY-NC-ND
416 Kose E. A. et al.
Introduction
Dexmedetomidine is a selective α₂ agonist for which labeled 
indication is intensive care unit (ICU) sedation. It can produce 
cooperative sedation associated with minimal respiratory 
depression and analgesia.1,2 Those properties make it useful 
in many clinical situations, including the sedation of ICU 
patients in whom the ability to perform frequent neurologic 
examination is of clinical importance. Additionally, because 
of the same properties, using this agent may be advanta-
geous in central nervous system related procedures such as 
awake craniotomy, carotid endarterectomy with regional 
anesthesia, carotid angioplasty and stenting.1,3 It can also 
be preferred as an adjuvant in general anesthesia because 
of the possibility of the early extubation and recovery of 
cognitive functions. In this way, it is possible to reveal the 
additional postoperative neurological deﬁ cits in early pos-
toperative period.4 The patients who are in ICU generally 
received concomitant medications such as vasopressors, 
vasodilators, digoxin, diuretics, beta blockers, aspirin, low 
molecular weight heparin that have all possible effects on 
platelet function. On the other hand, it is known that there 
are 250-300 α2-adrenoceptor on the surface of each human 
platelet and ephedrine activates platelets and induces 
their aggregation by binding these receptors.5 Ephedrine is 
considered a weak platelet agonist, the function which is 
mainly to sensitize platelets to other activating agents.6-9 
Due to the possibility of the increased risk of hemorrhage 
by drug interactions, it is important to clarify the effects of 
dexmedetomidine on platelet functions for other medications 
may have possible additive effects on platelet function. This 
study was designed to study platelet function after incuba-
tion with therapeutic concentrations of dexmedetomidine 
in healthy volunteers.
Materials and methods
After obtaining local ethic committee approval and informed 
consent, we carried out the study on 18 healthy, non-smoking 
males, ages ranging 25 to 35 years old (mean ± SD = 28.32 
± 4.35 years). We did not include subjects who had an ab-
normal platelet count, a history of thrombosis or abnormal 
bleeding, active neoplasia or active inﬂ ammatory disease. 
All studies were done in the morning with the volunteers 
fasting overnight and we ascertained that no drugs had 
been taken within 2 weeks before testing. The venous blood 
samples were drawn without a tourniquet with a 20-gauge 
needle from the antecubital vein. We anti-coagulated the 
samples with 3.8% 0.130 M sodium citrate solution (blood 
to anticoagulant ratio: 9/1). There was no hemolysis in 
samples. We kept them at room temperature and tested 
within 60 minutes of collection. We counted platelets using 
an automated cell counter device (Abbott Cell-Dyne 4000; 
Abbott Park, Chicago, IL, USA). 
Given the recommended therapeutic concentration ran-
ge of dexmedetomidine obtained by intravenous infusion is 
0.4-1.2 ng.mL-1 (Precedex® SPC; Abott Laboratories, Abbott 
Park, IL), we prepared dexmedetomidine solutions in three 
different concentrations which would yield 0.4 ng.mL-1, 0.8 
ng.mL-1 and 1.2 ng.mL-1 dexmedetomidine by using 0.9% so-
dium chloride as diluent. We used the diluent not including 
dexmedetomidine as control. After the determination of 
hematocrit values, we divided the blood samples into four 
equal parts. According to the amount of plasma (derived from 
the hematocrit), we added the calculated value of dexme-
detomidine solution and diluent without dexmedetomidine 
as control to blood sample (1 μL solution for 1 mL of plasma) 
and obtained 0, 0.4, 0.8 and 1.2 ng.mL-1  dexmedetomidine 
concentrations of plasma. Each concentration of dexme-
detomidine was incubated with whole blood at 37°C. After 
incubation for 15 minutes, blood samples were centrifugated 
(100 g, 10 minutes) to isolate platelet-rich plasma (PRP) 
from supernatant. We centrifuged the remainder of blood 
again (2,400 g, 20 minutes) to prepare platelet-poor plasma 
(PPP). The PRP was diluted with the PPP to yield test PRP 
with a ﬁ nal platelet count of 250 ± 50 X 109.L-1. Aggregation 
was performed using a turbidometric method (Chrono-log 
Corporation, Model 560-Ca; Havertown, PA, USA) according 
to the protocol of Chrono-log Corporation. We randomly 
changed the sequence by which different dilutions were 
studied in the aggregation, which was unknown to the persons 
performing the studies. We evaluated platelet aggregation 
response with adenosine diphosphate (ADP) (5 and 10 μM ﬁ nal 
concentrations), collagen (3 μg.mL-1 ﬁ nal concentrations) 
and epinephrine (10 μM ﬁ nal concentration). We obtained 
aggregating agents from Chrono-log Corporation. The device 
calculated dose-response cures automatically and evaluated 
them using amplitude and slope.
Statistical analysis
We analyzed data using the SPSS 11.5 (SPSS Inc. Software, 
Chicago, Illinois, USA) statistical software. Because the data 
were not normally distributed and the variations were not 
homogenous among all groups, we used Friedman repeated 
measure analysis of variance to compare platelet aggregation 
response to ADP, collagen or epinephrine between control 
and each dexmedetomidine solution. All data were presented 
as median and range. We considered p < 0.05 statistically 
signiﬁ cant.
Results
The platelet aggregation amplitudes and slopes were sta-
tistically similar among all groups by the aggregation test, 
performed with ADP, collagen or epinephrine (Table 1). 
Discussion
Dexmedetomidine, the dextro enantiomer of medetomidine, 
is a potent and highly selective α₂-adrenoreceptor agonist.1-3 
It is 8 to 10-fold more potent than clonidine for the α2-
adrenoceptors. By virtue of this potency, dexmedetomidine 
is considered to be a full agonist of the α2-adrenoceptors, 
which might permit its application in relatively high doses 
for sedation and analgesia without the unwanted vascular 
effects from activation of α1-adrenoceptors.
1-3 In addition to 
the administration in ICU as a sedative-analgesic agent, there 
have been a number of studies of lower doses of dexmedeto-
midine as an adjunct to anesthesia in cardiac and noncardiac 
surgical operations.10,11 On the other hand, human platelets 
have 250-300 α₂-adrenoreceptor on their surfaces.  Ephedrine 
activates platelets and induces their aggregation by binding 
these receptors.5 Alpha-adrenergic receptors of human pla-
telets are exclusively α2A subtype.
11 In vitro, stimulation of 
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platelet β2-adrenoreceptors blunts aggregation by increase of 
intracellular c AMP, and aggregatory response to epinephrine 
may be enhanced by non-selective blockage because of uno-
pposed α₂-adrenoreceptor stimulation.13,14 It was speculated 
that catecholamine surge might trigger a hypercoagulable 
state and enhance the odds of overt thrombosis in patients 
with atherosclerotic disease and hypertension.15-18 Martins 
et al. evaluated effects of dexmedetomidine on blood coa-
gulation by thromboelastography and concluded that dex-
medetomidine had signiﬁ cantly increased reaction time and 
decreased coagulation index in ﬁ nal curves as compared to 
initial values. They reported that, although dexmedetomidine 
had a mild hypocoagulative effect, coagulation remained 
within normal ranges.19 Although it is wise to think that de-
xmedetomidine may have a decreasing effect on thrombotic 
events during an operation which stimulates sympathetic 
nervous system and leads to increased catecholamine levels, 
it is never used as a sole agent, not in patients undergoing 
surgery nor in the ICU. Hence, it is important to clarify the 
effects of dexmedetomidine on platelet functions for other 
medications, which may have possible additive effects on 
platelet function. We designed this study because of the fact 
that we could not ﬁ nd any published investigation related 
to the effects of dexmedetomidine on platelet functions in 
English medical literature.
A study that investigated the effects of clonidine and 
its analogue para-aminoclonidine showed that both agents 
potentiated platelet aggregation induced by a submaximal 
concentration of ADP and epinephrine-induced aggregation 
in a dose-dependent fashion. Stamp et al. concluded that 
these two agents are partial agonists for the α2-adrenergic 
receptors on blood platelets and that this receptor exists 
predominantly in the low-afﬁ nity state in the intact cell.20 
Similarly, Petrusewicz et al. tested sixteen imidazole deri-
vative drugs with regards to their aggregatory and antia-
ggregarory effects on human blood platelets and found a 
signiﬁ cant inhibition of the epinephrine induced aggregation 
in a dose dependent fashion by using clonidine in their study.21 
In another study, it was shown that aggregation induced by 
ADP was potentiated by clonidine greater than or equal to 
epinephrine.22 In the present study, we used the recommen-
ded therapeutic dose range of dexmedetomidine in vitro 
and we could not ﬁ nd any statistically signiﬁ cant difference 
in platelet aggregation response to ADP (5 and 10 ﬁ nal con-
centrations), collagen (3 μg.mL-1  ﬁ nal concentrations) or 
epinephrine (10 μM ﬁ nal concentrations). While it is 8 to 10 
fold more potent than clonidine for the α2-adrenoceptors, 
the lack of the potentialisation of the platelet aggregation 
by using dexmedetomidine can be explained by the low do-
ses of dexmedetomidine. Additionally, it is notable that the 
increased platelet aggregation by which obtained clonidine 
in previous studies was also dose-dependent. Recent reports 
show that imidazole α-adrenergic agents inhibit epinephrine-
induced aggregation in canine platelets more effectively than 
non-imidazole ones.23 In a previous report, nonadrenergic 
imidazole-prefered binding sites were shown in human pla-
telets.24 Because both clonidine and dexmedetomidine have 
an imidazole structure, the imidazole structure could not be 
responsible for this situation. Although the results of platelet 
aggregation tests were not different with the therapeutic 
dose range of dexmedetomidine when compared with the 
control group in this study, these results may show an incre-
ased platelet aggregation with the usage of increased doses 
of the agent like clonidine. We preferred to study only the 
recommended dosage of this agent because of the fact that 
dexmedetomidine can cause unwanted cardiovascular effects 
with the usage of overdoses in clinical administration.
In conclusion, when used in similar concentrations to 
recommended dose-range, dexmedetomidine had no effect 
on the platelet functions in healthy individuals in vitro. 
However, platelet functions can be affected by several 
additional pathological and physiological mechanisms in 
clinical administration. Hence, it should be used cautiously 
especially if there is concomitant administration of the other 
medications, which can alter the platelet functions.
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